CORD-19:867ebb2be2d466bcb35e5a7319708eaff39c4799 / 537473-537743 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/867ebb2be2d466bcb35e5a7319708eaff39c4799","sourcedb":"CORD-19","sourceid":"867ebb2be2d466bcb35e5a7319708eaff39c4799","text":"Tedizolid phosphate 200mg, once-daily, 6-day treatment has been demonstrated to be non-inferior to linezolid 600 mg, twice-daily, 10-day treatment in patients with ABSSSI, which was further investigated in a multicentre phase 3 study in a predominantly Asian population.","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T50","span":{"begin":0,"end":270},"obj":"Sentence"}],"attributes":[{"subj":"T50","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"T45353","span":{"begin":0,"end":270},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T45353","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#c393ec","default":true},{"id":"CORD-19-Sentences","color":"#93eca9"}]}]}}